About UsProductsNewsClinical TrialCorporate RelationsResources

Recent Press Releases:

Upcoming Events

OFFICIAL RELEASE

Ash Access Technology, Inc. To Present Clinical Abstract of Zuragen™ (AAT-023) at the 39th Annual Meeting of the American Society of Nephrology

Dr. Stephen R. Ash, M.D. to Highlight In Vitro Efficacy Data of the Company’s Novel Antimicrobial / Antithrombotic Therapy for Catheter-Related Bloodstream Infection (CRBSI)

November 15, 2006 11:33 AM EST (Lafayette, Indiana) - - - Ash Access Technology, Inc., a privately-held biopharmaceutical and medical device company, today announced that Dr. Stephen R. Ash, M.D., Chairman of the Board and Director of Research will present a clinical abstract (#553192) of the in vitro efficacy data of Zuragen™ (formerly known as AAT-023) at the 39th Annual American Society of Nephrology Meeting in San Diego on Saturday, November 18.

Zuragen™ is a non-antibiotic, injectable therapy designed to significantly reduce the incidence of CRBSI and maintain catheter patency and will be administered to patients at the conclusion of each hemodialysis session. The product is currently being evaluated in a large pivotal trial that is a multi-centered study consisting of 16 sites and 400 hemodialysis patients. The clinical abstract demonstrates the rapid and broad spectrum antimicrobial and biofilm efficacy of Zuragen™ against the most common antibiotic-resistant strains of bacteria associated with CRBSI, including Staphylococcus aureus and Staphylococcus epidermidis, as well as the novel synergy of the product’s multiple components.

"CRBSI is a significant challenge patients and their providers face when using a catheter for vascular access. It is a problem that is difficult and costly to treat once diagnosed and associated with a high rate of mortality. Zuragen™ is an exciting technology that has tremendous potential to prevent life-threatening CRBSIs and their associated complications. We are confident the pivotal trial will validate the safety and efficacy of ZuragenTM and help establish a new therapeutic option, said Dr. Stephen R. Ash, M.D., Chairman and Director, Research and Development at Ash Access Technology, Inc.

The clinical trial has been made possible a by a generous two million dollar grant from the Indiana 21st Century Research and Technology Fund (see release for details) and a $2.7M SBIR Fast-Track Grant from the NIH NIDDK (details here). Together these substantial grants make it feasible to complete our nearly $7M clinical trial to evaluate Zuragen's antimicrobial and antithrombotic impact on patients undergoing dialysis through central venous catheters.

According to the Centers for Disease Control, the magnitude of CRBSI in the U.S is significant with an estimated 200,000 to 400,000 episodes annually. Studies have also shown that mortality rates associated with CRBSI range from 12 – 25% while annual healthcare costs associated with treating these infections may exceed $2 billion. Both the NNIS and CDC continue to report alarming rates of resistance to antibiotics (Vancomycin / Methicillin) of the most common strains of bacteria associated with CRBSI including Staphylococcus aureus, Staphylococcus epidermidis and Pseudomonis Agr.


Ash Access Technology, Inc. is a privately-held company founded to develop antimicrobial and vascular access technologies, devices and methodologies to combat the deadly and expensive problem of catheter-related bloodstream infections, with an emphasis on prevention. Dr. Stephen R. Ash, Chairman and Director, Research and Development, is a practicing Nephrologist with the Arnett Clinic in Lafayette, Indiana, and is a world-recognized researcher and patent holder in extracorporeal devices, sorbent chemistry, and vascular and peritoneal access devices. Ash Access Technology is located in Lafayette, Indiana in the INOK Business Center.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control.